TLR4 gene polymorphisms in Egyptian vitiligo patients: insights into emerging association with clinical activity, family history, and response to therapy

Journal of Genetic Engineering and Biotechnology

Table 5 Relation of TLR4 genotypes versus demographic, clinical, and outcome data in vitiligo group 1 (below 18 years) patients

SNPs		rs1927914			rs1927911			rs11536858
SNPs		CC N/%	CT N/%	TT N/%	CC N/%	CT N/%	TT N/%	AA N/%	AG N/%	GG N/%
Sex	M/F	0.20/0.03	0.20/0.15	0.60/0.81	0.10/0.15	0.80/0.69	0.10/0.15	0.20/0.24	0.70/0.57	0.10/0.18
Sex	p	0.13	0.66	0.15	1.0	0.53	1.0	1.0	0.48	1.0
Course	Regressive/Progressive	0.00/0.13	0.00/0.13	1.00/0.73	0.00/0.17	1.00/0.61	0.00/0.22	0.00/0.22	1.00/0.70	0.00/0.09
Course	p	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Psychiatric trauma	+/−	0.33/0.09	0.00/0.14	0.67/0.76	0.00/0.19	0.67/0.62	0.33/0.19	0.00/0.24	1.00/0.67	0.00/0.09
Psychiatric trauma	p	1.0	1.0	1.0	1.0	1.0	0.52	1.0	0.53	1.0
Alopecia	+/−	1.00/0.09	0.00/0.13	0.00/0.78	0.00/0.17	1.00/0.60	0.00/0.22	0.00/0.22	1.00/0.69	0.00/0.09
Alopecia	p	0.13	1.0	0.25	1.0	1.0	1.0	1.0	1.0	1.0
FH of vitiligo	+/−	0.25/0.10	0.25/0.10	0.50/0.80	0.25/0.15	0.50/0.65	0.25/0.20	0.00/0.25	1.00/0.65	0.00/0.10
FH of vitiligo	p	0.44	0.44	0.25	0.54	0.62	1.0	0.54	0.28	1.0
FHAIDs	+/−	0.00/0.14	0.50/0.09	0.50/0.77	0.50/0.14	0.00/0.68	0.50/0.18	0.00/0.23	1.00/0.68	0.00/0.09
FHAIDs	p	1.0	0.24	0.45	0.31	0.13	0.38	1.0	1.0	1.0
Remission	+/−	0.29/0.06	0.14/0.12	0.57/0.85	0.43/0.06	0.43/0.71	0.14/0.24	0.29/0.18	0.57/0.77	0.14/0.06
Remission	p	0.19	1.0	0.31	0.06	0.36	1.0	0.61	0.37	0.51
Type	Segmental/Nonsegmental	0.00/0.15	0.00/0.15	0.00/0.30	0.00/0.20	0.75/0.60	0.20/0.20	0.00/0.25	1.00/0.65	0.00/0.10
Type	p	1.0	1.0	0.54	1.0	1.0	1.0	0.54	0.28	1.0

M/F male/female, R/P regressive/progressive, Seg/Nonseg segmental/nonsegmental, FH family history, FHAIDs family history of auto-immune diseases, p value significant if < 0.05
Fischer Exact test: no significant associations were detected